Abiraterone for treatment of germline mutation in BRCA1 gene with low age, high tumor burden and rapid progression of prostate cancer: a case report
10.3760/cma.j.cn112330-20210408-00007
- VernacularTitle:阿比特龙治疗胚系BRCA1基因突变的低年龄、高肿瘤负荷、快速进展前列腺癌一例报告
- Author:
Shuo WANG
1
;
Shouzhen CHEN
;
Yaofeng ZHU
;
Hu GUO
;
Benkang SHI
Author Information
1. 山东大学齐鲁医院泌尿外科，济南 250012
- Keywords:
Prostatic neoplasms;
BRCA1 germline mutation;
Abiraterone acetate
- From:
Chinese Journal of Urology
2021;42(Z1):27-29
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of prostate cancer is increasing year by year in China. People with BRCA mutation are at high risk of prostate cancer. However, there is no clear and effective treatment for mHSPC with high metastatic load carrying BRCA mutation. In this study, we report a mHSPC patient with high metastatic burden and germline BRCA1 gene mutation who rapidly progressed to mCRPC after traditional CAB therapy and then received ADT combined with abiraterone and achieved significant PSA response, suggesting that ADT combined with abiraterone may be an effective therapy for mHSPC patients with BRCA1 germline mutation.
